Theravance Biopharma Inc(TBPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | - | P/E | 16.87 | EPS (ttm) | 1.01 | Insider Own | - | Shs Outstand | 51.9M | Perf Week | - |
| Market Cap | 0.88B | Forward P/E | 9.73 | EPS next Y | -37.5% | Insider Trans | - | Shs Float | 48.7M | Perf Month | 0.06% |
| Enterprise Value | 0.57B | PEG | - | EPS next Q | 0.32 | Inst Own | 79.38% | Short Float | 3.46% | Perf Quarter | 0.77% |
| Income | 0.05B | P/S | 8.47 | EPS this Y | 35.92% | Inst Trans | - | Short Ratio | 1.95 | Perf Half Y | 4.16% |
| Sales | 0.10B | P/B | 3.05 | EPS next 5Y | -9.64% | ROA | 12.01% | Short Interest | 1.69M | Perf YTD | -8.98% |
| Book/sh | 5.58 | P/C | 2.28 | EPS past 3/5Y | - | ROE | 20.91% | 52W High | -19.02% ($21.03) | Perf Year | 21.04% |
| Cash/sh | 7.47 | P/FCF | 16.45 | Sales past 3/5Y | 27.91% 8.38% | ROIC | 15.36% | 52W Low | 30.2% ($13.08) | Perf 3Y | 86.94% |
| Dividend Est. | - | EV/EBITDA | 70.92 | EPS Y/Y TTM | 331.61% | Gross Margin | 94.45% | Volatility(W/M) | 0.22% 0.3% | Perf 5Y | 140.2% |
| Dividend TTM | - | EV/Sales | 5.44 | Sales Y/Y TTM | 35.11% | Oper. Margin | 2.12% | ATR (14) | 0.06 | Perf 10Y | -52.42% |
| Dividend Ex-Date | - | Quick Ratio | 13.54 | EPS Q/Q | -110.56% | Profit Margin | 51.58% | RSI (14) | 53.28 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.54 | Sales Q/Q | -20.86% | SMA20 | -0.07% ($17.04) | Beta | 0.18 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.25 | Earnings | 2026/8/10 | SMA50 | 0.39% ($16.96) | Rel Volume | 0 | Prev Close | $17.03 |
| Employees | 90 | LT Debt/Eq | 0.21 | EPS/Sales Surpr. | -251.72% -7.84% | SMA200 | -0.87% ($17.18) | Avg Volume(3M) | 0.87M | Price | $17.03 |
| IPO | 2014/5/16 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
Theravance Biopharma is a biotech company built around respiratory therapeutic assets. It shares the U.S. commercialization revenue from its lead asset, YUPELRI (revefenacin) inhalation solution, with its partner, while also collecting revenue from royalties on partner assets such as the legacy TRELEGY royalty. The ticker is TBPH. Recently, the company has significantly scaled back its in-house drug development and restructured its business around a royalty and revenue collection model.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
TBPH makes money exceptionally well
Of every $100 in sales, $2.12 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +35.9% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $1,687. Peers typically go for $806. Compared with its own 2-year average, it is 122% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +140.2%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 79.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #157 of 599 in the industry
Based on market cap of $884M.
FAQ
TBPH belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of TBPH is approximately $884M, ranking 2,693 within its sector.
TBPH has a P/E ratio of approximately 16.9x, which can be used to assess its valuation relative to the Healthcare sector average.
TBPH has recorded a 52-week high of $21.03 and a low of $13.08.